ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
0,00%
Dow Jones
37 903,29
0,23%
DAX
17 921,95
0,00%
Brent Oil
83,84
0,36%
Bitcoin
57 770,48
-0,80%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AcelRX Pharmaceuticals Inc (ACRX)

  7. AcelRX Pharmaceuticals Inc (ACRX) Actualités

ACRX AcelRX Pharmaceuticals Inc

0,86
0,00 (0,00%)
02 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
AcelRX Pharmaceuticals Inc ACRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,86 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,86
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202422:25EDGAR2Form ARS - Annual Report to Security Holders
29/4/202422:24EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/4/202422:23EDGAR2Form DEF 14A - Other definitive proxy statements
19/4/202422:37EDGAR2Form 8-K - Current report
21/3/202421:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/3/202421:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202415:17EDGAR2Form 8-K - Current report
09/1/202415:05PRNUSAcelRx Announces Rebranding With Name Change to Talphera,..
14/12/202314:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202322:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202314:30PRNUSAcelRx Pharmaceuticals Announces Publication of Study..
22/11/202322:38EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202322:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/11/202312:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:14EDGAR2Form 8-K - Current report
08/11/202322:05PRNUSAcelRx Reports Third Quarter 2023 Financial Results and..
07/11/202322:05PRNUSAcelRx to Host KOL Panel Discussion on Current Anticoagulant..
26/10/202322:30PRNUSAcelRx to Host Third Quarter 2023 Financial Results Call and..
20/10/202322:30EDGAR2Form 8-K - Current report
10/10/202322:17EDGAR2Form 8-K - Current report
05/10/202322:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
05/10/202322:30EDGAR2Form 8-K - Current report
03/10/202314:30PRNUSAcelRx Receives IDE Approval for Niyad and Advances to a..
22/9/202323:18EDGAR2Form 8-K - Current report
12/9/202301:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202314:30PRNUSAcelRx Pharmaceuticals to Participate in the H.C. Wainwright..
28/8/202312:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202312:34EDGAR2Form DEF 14A - Other definitive proxy statements
25/8/202322:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202318:45EDGAR2Form 144 - Report of proposed sale of securities
24/8/202322:23EDGAR2Form 144 - Report of proposed sale of securities
10/8/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:10EDGAR2Form 8-K - Current report
10/8/202322:05PRNUSAcelRx Reports Second Quarter 2023 Financial Results and..
09/8/202323:29EDGAR2Form 424B7 - Prospectus [Rule 424(b)(7)]
02/8/202312:06EDGAR2Form S-3 - Registration statement under Securities Act of..
27/7/202322:05PRNUSAcelRx to Host Second Quarter 2023 Financial Results Call..
21/7/202314:15EDGAR2Form 8-K - Current report
21/7/202314:00PRNUSAcelRx Pharmaceuticals Announces Closing of Previously..
18/7/202314:00PRNUSAcelRx Pharmaceuticals Announces $10 Million Private..
10/5/202322:05PRNUSAcelRx Pharmaceuticals Reports First Quarter 2023 Financial..

Dernières Valeurs Consultées

NASDAQ
ACRX
AcelRX Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés